Hepatic effects of glucagon receptor agonism: the mechanistic worry posts 31–57

Worth separating two things that post #27 runs together.

The question underneath hepatic effects of glucagon receptor is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

Reading rather than answering, but this is the post I would point somebody at.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

The right answer here may simply be that it has not been measured.

Where I have landed on hepatic effects of glucagon receptor, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.

Discontinuation for adverse effects in phase 2 was not negligible at the higher doses. That figure belongs next to the efficacy figure whenever the efficacy figure is quoted.

I have seen it go both ways, which is why I hedge.

The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.

The short answer was in the first line; everything after is the working.

On hepatic effects of glucagon receptor: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

Post #35 answers the question as asked. The question underneath it is different.

Answering the hepatic effects of glucagon receptor question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

That is all the detail I have. Someone else will have more.

Adding the measurement that post #39 says would settle it.

Reading back through the hepatic effects of glucagon receptor threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.

Narrowing post #40, because the general version has more than one answer.

Offering a way to settle hepatic effects of glucagon receptor rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.

Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.

That is the version I would defend. It is not the version I started with.

Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work.

I have separated what I observed from what I concluded, which does not always happen.

Post #42 and I disagree about the size of the effect, not about the direction.

If you are new and reading this thread for the answer to hepatic effects of glucagon receptor: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.